Introduction
Patients with rheumatoid arthritis (RA), have a two-to three-fold increased risk of atherosclerotic cardiovascular disease (CVD), the major cause of mortality in these individuals. [1] [2] [3] Identifying CVD risk in these patients remains challenging. [4] [5] [6] Currently, risk is calculated based on methodologies used for the general population, which are often an underestimate. 4, 6 This highlights the need to better understand the relationship between RA and CVD, first, in order to accurately identify patients at risk, and second, in order to treat and reduce CV events. The mechanisms that cause accelerated atherosclerotic-CVD in RA are unclear, although systemic inflammation is thought to play a central role. [7] [8] [9] [10] [11] Consistent with this hypothesis, patients with RA often have increased circulating monocytes 12, 13 and platelets. 14, 15 It is well documented that circulating monocyte levels correlate with CVD in humans, 16 and animal studies have demonstrated a causal relationship between circulating levels of monocytes and platelets with atherogenesis [17] [18] [19] [20] [21] [22] [23] and impaired atherosclerotic lesion regression. 20 While the involvement of monocytes in joint pathology has been previously studied, 24 the association of myeloid cells and atherosclerosis in RA has not yet been investigated. Monocytes, neutrophils, and platelets are produced in the bone marrow (BM) from haematopoietic stem and progenitor cells (HSPCs) through a process termed myelopoiesis. Maintaining cellular cholesterol homeostasis in HSPCs is essential to maintain normal haematopoiesis. 18, 19, 23 Accumulation of cellular cholesterol results in hyperproliferation, myeloid skewing and, consequently, increased myelopoiesis. Haematopoietic stem and progenitor cells and myeloid progenitors regulate cholesterol efflux through the ATP binding cassette transporters (ABC)-A1 and ABCG1, and their cell intrinsic ligand apolipoprotein-E (apoE). 18, 23 Interestingly, patients with RA appear to have defective cholesterol metabolism, through the downregulation of ABCA1 and ABCG1. 25, 26 These defects in cholesterol metabolism may alter cellular cholesterol homeostasis, contributing to enhanced CVD risk. Moreover, deletion of key components of the cholesterol efflux pathway amplifies autoimmune-like phenotypes, revealing an intimate link between autoimmune disorders, inflammation, cholesterol metabolism and, potentially, CVD. [27] [28] [29] [30] [31] We hypothesized that systemic inflammation associated with RA would drive enhanced and sustained myelopoiesis, associated with a central defect in HSPC cholesterol metabolism that causes increased growth factor receptor expression. Consequently, these alterations in cholesterol metabolism may impair atherosclerotic lesion regression or alter lesion progression in pre-clinical models of atherosclerosis. 
Methods

Results
Murine models of rheumatoid arthritis exhibit monocytosis, neutrophilia, and thrombocytosis
First, we confirmed leucocytosis in two murine models of RA. CIA caused Ly6-C hi -driven monocytosis and prominent neutrophilia, along with thrombocytosis and reticulated thrombocytosis ( Figure 1A-D) . These findings were consistent with literature 24 and were replicated in the K/BxN model of RA ( Figure 1E-H) . Thus, animal models of RA recapitulate the blood profile observed in RA patients.
Rheumatoid arthritis promotes myelopoiesis and extramedullary haematopoiesis
To investigate the mechanisms contributing to the increased abundance of circulating myeloid cells, we characterized the BM in both arthritis models. We observed a robust expansion and enhanced proliferation of HSPCs and myeloid progenitor subsets, common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), and the megakaryocyte-erythroid progenitors (MEPs) ( Figure 2A -C and H-J). Platelet production is tightly regulated by thrombopoietin (TPO), which we found to be elevated in both models of RA (Supplementary material online, Figure S1A and B).
We also observed an increase in the abundance of circulating HSPCs and myeloid progenitors in arthritic mice, suggesting active
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Rheumatoid arthritis (RA) elevates the risk of mortality from cardiovascular disease (CVD), independent of traditional CVD risk factors. Our findings in mouse and man suggest that sustained, RA-driven inflammation could be a causal determinant of lesion severity in atherosclerosis. RA is associated with persistent leucocytosis and defects in cellular cholesterol handling. Additionally, monocytosis may present as an alternative factor to consider when determining CV risk in patients. In an experimental model of RA, we found impaired plaque regression, and altered progression of atherosclerosis, with enhanced monocyte infiltration into the plaque increasing the macrophage burden and generating an unstable plaque phenotype. This could be reduced by administration of the cholesterol acceptor, reconstituted high-density lipoprotein (rHDL). Thus, we suggest that modulation of cellular cholesterol (i.e. with rHDL or statins), could limit CVD in RA, even if cholesterol levels are not elevated. Figure 2D and K) . Additionally, we noted splenomegaly, and an expansion of splenic HSPCs, CMPs, GMPs, and MEPs in both models of RA, confirming extramedullary haematopoiesis ( Figure 2E , F, L, and M). As the spleen is an important organ for producing inflammatory monocyte subsets that track into atherosclerotic lesions, 32 we assessed the abundance of mature splenic myeloid cells. Consistent with this atherogenic pathway, we found an increase in total monocytes, driven by the Ly6-C hi subset, and dramatically higher neutrophils in the spleens of mice with inflammatory arthritis ( Figure 2G and N). These findings collectively provide evidence that both medullary and extramedullary organs are involved in enhanced myelopoiesis in the setting of polyarticular joint inflammation.
Bone marrow haematopoietic stem and progenitor cells from murine inflammatory arthritis models display defects in cholesterol metabolism Figure 3A and B). This was associated with a down-regulation in the expression of the cholesterol efflux genes Apoe, Abca1, and Abcg1 in the HSPCs ( Figure 3C and Supplementary material online, Figure S2A and B). Consistent with genetically deficient models with augmented membrane lipid rafts (i.e. Apoe À/À and Abca1 À/À /Abcg1 À/À ), 18, 23 we observed increased cell surface levels of the common b-subunit of the interleukin (IL)-3/granulocyte-macrophage-colony stimulating factor (GM-CSF) receptor (IL-3Rb; CD131) and M-CSF receptor (M-CSFR; CD115) on BM HSPCs, CMPs, and GMPs of arthritic mice (Supplementary material online, Figure S3A and B). We also found an increase in mRNA expression of Il-3rb, M-csfr, G-csfr, and Gm-csfr in the CMPs isolated from mice with CIA (Supplementary material online, Figure S3C ) and sustained higher expression of Il-3rb and G-csfr in GMPs (Supplementary material online, Figure S3D ). Taken together, these data suggest that defective cholesterol metabolism plays an important role in sustained proliferation and stem cell skewing towards the myeloid lineage during inflammatory arthritis.
Circulating myeloid cells from arthritic mice have persistent cholesterol dysregulation
Impaired cholesterol efflux in mature myeloid cells, including monocytes and macrophages, promotes foam cell development, contributing to enhanced atherogenesis. 31, 34 We postulated that this might also be occurring in mature myeloid cells in the arthritic mice, which could promote transition to lipid-laden macrophages in the atherosclerotic lesion. 35 Monocytes (Ly6-C hi and Ly6-C lo ) and neutrophils showed down-regulation of Abca1 and Apoe, and significantly increased membrane cholesterol ( Figure 3D and E and Supplementary material online, Figure S3E -G). These findings were independent of plasma cholesterol levels (Supplementary material online, Figure S3H ), suggesting that the suppression of key efflux genes in haematopoietic stem cells are retained during myelopoiesis.
Systemic inflammation drives enhanced haematopoiesis
We explored whether defects in cellular cholesterol metabolism might be responsible for driving the enhanced monocyte production or if these cholesterol disturbances are a consequence of systemic inflammation in experimental RA. To distinguish between these possibilities, we determined if HSPCs with defective cholesterol efflux would outcompete WT HSPCs in mice with inflammatory arthritis. This was achieved by performing a competitive bone marrow transplant (cBMT). Equal portions of WT CD45.1 and Apoe À/À CD45.2 BM were transplanted into irradiated WT mice. Following BM reconstitution, a group of transplanted mice were rendered arthritic using the K/BxN serum transfer model ( Figure 3F and Supplementary material online, Figure S4 ). As expected, leucocytosis and thrombocytosis was observed in arthritic mice with WT/Apoe from the genotypes ( Figure 3L ). To confirm the persistent downregulation in cholesterol metabolism, we sorted the HSPCs based on expression of CD45.1 and CD45.2 from the control and arthritic mice and examined the level of Abca1 mRNA. Consistent with a systemic effect of inflammatory arthritis on the HSPCs, we found a significant down-regulation of Abca1 in both the WT CD45.1 and Apoe À/À CD45.2 HSPCs from the arthritic mice compared with the respective genotypes isolated from the control mice ( Figure 3M ). These results confirm that the disturbances in cellular homeostasis are a consequence of inflammatory arthritis. We next explored if the inflammatory cytokines that are known to be involved in the pathogenesis of RA are directly capable of downregulating the cholesterol efflux genes in HSPCs. To assess this, we incubated HSPC-enriched BM from WT mice in serum isolated from control or CIA mice and observed a down-regulation of Apoe and Abca1 (Supplementary material online, Figure S5A ). To shed light on which cytokine(s) might be involved in this pathway, HSPC-enriched BM was treated with a cocktail of RA-associated cytokines (GM-CSF, TNF-a, IL-1b, and IL-6). This experiment confirmed that inflammatory cytokine signalling induced the down-regulation of these genes (Supplementary material online, Figure S5B ). We also examined these cytokines individually and found that while they each decreased the expression of Apoe and Abca1 in HSPC-enriched BM, there were differential effects on these genes, adding to the complexity of this disease and the interplay with cellular cholesterol metabolism (Supplementary Figure S5C and D) . Taken together, these data reveal that systemic inflammation found in RA down-regulates cholesterol efflux genes and promotes enhanced myelopoiesis. 
Rheumatoid arthritis impairs atherosclerotic lesion regression
Rheumatoid arthritis generally affects middle-aged adults with existing atherosclerosis, therefore we performed a lesion regression study. Female Ldlr À/À mice were placed on a western type diet (WTD) for 14 weeks to initiate atherogenesis. At this time-point, a subset of mice was euthanized for baseline atherosclerotic lesion characterization, while the remaining mice were switched to a chow diet to reduce circulating cholesterol levels and initiate lesion regression. Following 1 week on chow, a subgroup of mice were rendered arthritic (K/BxN), while the remaining mice provided a control regression group ( Figure 4A and B) .
Compared to baseline, 3 weeks on a chow diet resulted in a significant reduction in plasma cholesterol in both groups ( Figure 4C ). While atherosclerotic lesions in the control group regressed compared with baseline, this was impaired in the arthritic mice ( Figure 4D ). Further examining lesion characteristics, we confirmed the expected reduction in plaque lipid content and macrophage abundance in the control regression mice ( Figure 4E and F) . This was not seen in the plaques of arthritic mice, where a significant lipid and macrophage burden remained ( Figure 4E and F) . To explore lesion remodelling, we examined the collagen content of the plaques. This revealed an increasing trend in the control regression mice, which was not observed in the arthritic mice (Supplementary material online, Figure S6 ).
Lesional macrophages arise predominantly from blood monocytes, which can impair lesion regression. 20, 36, 37 Similar to our observations in WT mice (Figure 1) , we confirmed enhanced myelopoiesis and splenomegaly in arthritic Ldlr À/À mice ( Figure 4G and H). To provide further insight into impaired lesion regression in mice with inflammatory arthritis, we also found reticulated thrombocytosis, signifying enhanced platelet production/turnover, increased reactive immature platelets in Ldlr À/À K/BxN regression mice ( Figure 4I ) and enhanced plateletleucocyte interactions ( Figure 4J) . Each of these features is linked to enhanced atherogenesis.
17,38 
Rheumatoid arthritis enhances Ly6-C hi monocyte entry and macrophage abundance in atherosclerotic lesions: reversal by reconstituted high-density lipoprotein
We queried whether RA-driven monocytosis directly contributed to enhanced monocyte lesion entry in an atherosclerotic progression model. Additionally, we aimed to explore if administering a bolus of reconstituted HDL (rHDL), which can promote cholesterol efflux via passive diffusion, 30 could inhibit monocytosis and improve lesion outcomes. Apoe À/À mice were randomized into three experimental groups for 1 week of treatment; (i) control, (ii) K/BxN induced arthritis, and (iii) K/BxN and treated with rHDL ( Figure 5A and B) . To explore the role of monocytes in this context, we employed two methods of monocyte labelling. Mice were administered fluorescent tracking beads and EdU to label Ly6-C lo and Ly6-C hi monocytes, respectively 20, 37 ( Figure 5A and Supplementary material online, Figure S7A ). Administration of rHDL had no impact on clinical score but effectively reduced Ly6-C hi monocytes ( Figure 5B and C) . Exploring monocyte recruitment into atherosclerotic lesions, we observed an approximately three-fold increase in the abundance of Ly6-C þ cells in the plaques of arthritic mice, compared to control ( Figure 5D ). Consistent with peripheral blood monocytes, rHDL also reduced the abundance of Ly6-C þ cells within lesions ( Figure 5D ). The numbers of Ly6-C þ cells within lesions appeared to be due to the entry of EdU þ cells but not Ly6-C lo monocytes ( Figure 5E and Supplementary material online, Figure S7B ). EdU could also mark proliferative cells within lesions, but this is unlikely to occur as proliferation only occurs in advanced plaques. 39 When examining the lesion characteristics, we observed no change in lesion size in this shortterm experiment (Supplementary material online, Figure S7C ). However, arthritic mice displayed a significant increase in plaque macrophages, which was reduced with rHDL treatment, most likely explained by modulation of monocyte production and consequently recruitment ( Figure 5F ). Again, there was no change in circulating cholesterol levels between the groups (Supplementary material online, Figure S7D ). Together, these data show the direct involvement of monocyte entry into atherosclerotic lesions, which subsequently influences the plaque complexity in RA, and confirms the link with cholesterol metabolism, as rHDL reversed this phenotype. 
Rheumatoid arthritis patients display monocytosis and defects in cholesterol efflux genes
We next aimed to determine if our findings in pre-clinical models of arthritis, were evident in man. Patients and healthy controls were age and sex matched. Patients with RA were receiving treatment for active disease, including oral glucocorticoids and synthetic or biological disease modifying anti-rheumatic drugs (DMARDs; Table 1) . Despite these therapies, and consistent with previous literature, 12, 13 there was an increase in total monocytes, driven by a robust, approximately two-fold increase in the intermediate (
and non-classical (CD14 dim CD16 þþ ) subsets ( Figure 6A-E) . These monocyte subsets, have also been associated with adverse CVD-outcomes. 40, 41 We explored the mRNA expression of cholesterol efflux genes in peripheral blood mononuclear cells from RA patients. This revealed a significant reduction in LXR-A (NR1H3), ABCA1, and ABCG1 ( Figure 6F ). Taken together, these data suggest that our discoveries in the experimental models of RA in mice are clinically translatable.
Discussion
RA is a chronic inflammatory disorder that significantly increases the risk of CVD, 1,9-11 independent of traditional risk factors, 7,9,10 making CVD-risk assessment challenging. [4] [5] [6] We found that inflammatory arthritis impairs atherosclerotic lesion regression and accelerates atherogenesis in pre-clinical models of RA, independent of plasma cholesterol (Take home figure) . RA was associated with prominent leucocytosis and thrombocytosis, providing a potential explanation for the changes in atherosclerosis. We also found that the BM HSPCs from arthritic mice have dysregulated cellular cholesterol metabolism due to systemic inflammation. Furthermore, downstream myeloid cells retained this defect in cholesterol metabolism which could, in addition to enhanced myelopoiesis, contribute to foam cell development and increased CV events in RA. An emerging concept is that systemic inflammation in RA could be responsible for the increased CVD risk in these patients. 9 In keeping with this hypothesis, we observed increased circulating myeloid cells, platelets, and leucocyte-platelet interactions in arthritic mice, a profile previously shown to be causal in atherosclerotic development. 16 The enhanced abundance of platelets was paralleled by increased TPO levels, suggesting a link between inflammation in peripheral tissues and the liver. 42 Known to enter atherosclerotic lesions, 32 inflammatory Ly6-C hi blood monocytes where increased in arthritic mice.
Furthermore, we found an expansion of total monocytes in RA patients, predominantly due to a doubling of both the intermediate and the non-classical monocytes. This finding is consistent with previous reports that have shown an increase in CD16 þ monocytes, 13, 41, [43] [44] [45] which are inflammatory and commonly associated with CVD. 41, [46] [47] [48] Importantly, we have shown that cellular cholesterol dysfunction, which contributes to monocytosis in RA, is unlikely to be caused by only one particular cytokine. Thus, cellular cholesterol metabolism appears to be influenced by the multiple inflammatory cytokines which are upregulated in RA.
Cellular cholesterol handling is known to be important in atherosclerosis, independent of total circulating cholesterol. 34 Cholesterol efflux in RA patients appears to be defective, potentially mediated via ABC-transporters. 25, 26, 49 We found BM HSPCs from arthritic mice have reduced expression of Abca1, Abcg1, and Apoe, with the functional consequence of increased cell membrane cholesterol. This phenotype is similar to the genetic deletion of these genes where an increase in the cell surface expression of IL-3Rb was observed, promoting cell intrinsic proliferation and myeloid skewing. 18, 23 However, disruption of the efflux pathway achieved by deletion of Apoe resulted in no competitive advantage over WT HSPCs (i.e. cell extrinsic). These finding are consistent with mechanisms of systemic inflammation, presumably originating from peripheral sites, 50 instructing
HSPCs to down-regulate cholesterol efflux genes in order to sustain higher rates of proliferation. Our findings show that cellular cholesterol defects in HSPCs are retained in circulating monocytes in RA. It is possible that the impaired atherosclerotic lesion regression observed in mice with inflammatory arthritis could be initiated by early lineage-restricted changes in cholesterol metabolism. Daughter monocytes may then enter the lesion harbouring an increased cellular cholesterol, exacerbating foam cell formation. 35 Consistent with this hypothesis, macrophage specific deletion of Abca1/Abcg1 promotes atherogenesis 34 ; however, this phenotype is far more prominent when these transporters are deleted in HSPCs and the downstream myeloid cells. 23 Take home figure Rheumatoid arthritis impairs atherosclerotic regression, independent of circulating cholesterol levels. Systemic inflammation in rheumatoid arthritis causes an accumulation of cellular cholesterol in bone marrow haematopoietic stem and progenitor cells that contributes to enhanced proliferation and myeloid skewing towards myeloid progenitors. Enhanced myelopoiesis causes increased levels of circulating monocytes (monocytosis), neutrophils (neutrophilia), and platelets (thrombocytosis). Rheumatoid arthritis promotes increased Ly6-C hi monocyte entry into lesions, and consequently increases macrophage burden. Rheumatoid arthritis impairs the regression of established atherosclerotic lesions, which contained more macrophages and lipid, even when cholesterol levels were controlled. Therefore, rheumatoid arthritis appears to impair atherosclerotic lesion regression, associated with an expansion of myeloid cells and disturbed cellular cholesterol handling, independent of plasma cholesterol levels. Promoting cholesterol efflux with reconstitute high-density lipoprotein could reverse the abundance and entry of monocytes into the lesion, and consequently reduce plaque macrophage burden.
. We also found that inflammatory arthritis enhances atherogenesis by increasing Ly6-C hi monocyte entry into atherosclerotic lesions, causing an increased burden of macrophages. Interestingly, a link between cellular cholesterol metabolism and inflammatory autoimmune diseases is emerging through the characterization of genetic models of impaired cholesterol efflux 28, 30 ; however, a causal relationship has not been reported in man.
Targeting cellular cholesterol metabolism (as opposed to circulating levels) may be of most importance in inflammatory diseases, such as RA. Administration of rHDL limits the autoimmune phenotype in mice lacking Abca1/Abcg1 in CD11c expressing cells 30 and reduces atherogenesis in Apoe À/À mice. 51 Similar to these findings, infusion of rHDL in the setting of inflammatory arthritis was also able to overcome the decrease in ABC-transporter expression and reverse the inflammation-induced changes in lesion development, independent of the progression of arthritis. However, more frequent dosing of apoA-I and rHDL has been shown to inhibit arthritis in rats, 52 suggesting rHDL may also be useful adjunct therapy for acute arthritic flares. Importantly, rosuvastatin can induce carotid plaque regression in RA patients, independent of lipid lowering. 53, 54 This is likely due to the inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA) reductase, the molecular target of statins, that block cellular cholesterol synthesis and alter cellular metabolism, which in immune cells promotes anti-inflammatory effects. 55 This study highlights that normal cholesterol levels do not necessarily equate to vascular protection. Based on our findings, we postulate that even if people with RA do not have hypercholesterolaemia, administration of a statin is worth consideration. Our findings in mouse and man suggest that sustained, RA-driven inflammation could be a causal determinant of lesion severity in atherosclerosis. [17] [18] [19] [20] [21] [22] [23] We found evidence for enhanced myelopoiesis during inflammatory arthritis and also identified defects in cholesterol efflux pathways in HSPCs that were retained in mature myeloid cells. These features developed in spite of normal cholesterol levels. Thus, restoring cholesterol efflux could be a potential avenue to promote atherosclerotic lesion regression in RA. Importantly, inhibiting one cytokine alone in RA may not be sufficient to protect against atherosclerosis, as multiple cytokines can play a role. To date, simply enhancing cholesterol efflux potential by raising HDL in patients with CVD has not yielded any meaningful success with respect to lowering CV events. 56, 57 Thus, further understanding the mechanisms causing the suppression of cholesterol efflux genes in HSPCs and mature myeloid cells could reveal novel targets to promote lesion regression in RA, other autoimmune disorders associated with CVD, and in the general population.
